BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced results from its Phase 2a multi-center, open-label, dose-escalation clinical study of 6R-BH4 in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE